CHAPTER 1 22 1 49. Ferrari MD, Odink J, Tapparelli C, et al. Serotonin metabolism in migraine. Neurology. 1989;39(9):1239-1242. 50. Onderwater GLJ, van Dongen RM, Harms AC, et al. Cerebrospinal fluid and plasma amine profiles in interictal migraine. Ann Neurol. 2022; 93(4):715-728 51. Ashina M, Bendtsen L, Jensen R, Schifter S, Olesen J. Evidence for increased plasma levels of calcitonin gene-related peptide in migraine outside of attacks. Pain. 2000;86(1-2):133-138. 52. Cernuda-Morollon E, Larrosa D, Ramon C, et al. Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine. Neurology. 2013;81(14):1191-1196. 53. Fan PC, Kuo PH, Chang SH, et al. Plasma calcitonin gene-related peptide in diagnosing and predicting paediatric migraine. Cephalalgia. 2009;29(8):883-890. 54. Fekrazad R, Sardarian A, Azma K, et al. Interictal levels of calcitonin gene related peptide in gingival crevicular fluid of chronic migraine patients. Neurol Sci. 2018;39(7):1217-1223. 55. Fusayasu E, Kowa H, Takeshima T, Nakaso K, Nakashima K. Increased plasma substance P and CGRP levels, and high ACE activity in migraineurs during headache-free periods. Pain. 2007;128(3):209-214. 56. Jang MU, Park JW, Kho HS, Chung SC, Chung JW. Plasma and saliva levels of nerve growth factor and neuropeptides in chronic migraine patients. Oral Dis. 2011;17(2):187-193. 57. Rodriguez-Osorio X, Sobrino T, Brea D, et al. Endothelial progenitor cells: a new key for endothelial dysfunction in migraine. Neurology. 2012;79(5):474-479. 58. Gallai V, Sarchielli P, Floridi A, et al. Vasoactive peptide levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally. Cephalalgia. 1995;15(5):384-390. 59. Goadsby PJ,Edvinsson L,Ekman R.Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol. 1990;28(2):183-187. 60. Juhasz G, Zsombok T, Modos EA, et al. NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release. Pain. 2003;106(3):461-470. 61. Sarchielli P, Alberti A, Codini M, Floridi A, Gallai V. Nitric oxide metabolites, prostaglandins and trigeminal vasoactive peptides in internal jugular vein blood during spontaneous migraine attacks. Cephalalgia. 2000;20(10):907-918. 62. Gupta R, Ahmed T, Banerjee B, Bhatia M. Plasma calcitonin gene-related peptide concentration is comparable to control group among migraineurs and tension type headache subjects during inter-ictal period. J Headache Pain. 2009;10(3):161-166. 63. Lee MJ, Lee SY, Cho S, Kang ES, Chung CS. Feasibility of serum CGRP measurement as a biomarker of chronic migraine: a critical reappraisal. J Headache Pain. 2018;19(1):53. 64. Oterino A,Toriello M, Palacio E, et al. Analysis of endothelial precursor cells in chronic migraine: a case-control study. Cephalalgia. 2013;33(4):236-244. 65. Tvedskov JF, Lipka K, Ashina M, et al. No increase of calcitonin gene-related peptide in jugular blood during migraine. Ann Neurol. 2005;58(4):561-568. 66. Diener H-C. CGRP antibodies for migraine prevention — new kids on the block. Nature Reviews Neurology. 2019;15(3):129-130. 67. Edvinsson L, Haanes KA, Warfvinge K, Krause DN. CGRP as the target of new migraine therapies - successful translation from bench to clinic. Nat Rev Neurol. 2018;14(6):338-350. 68. Goadsby PJ, Edvinsson L. Human in vivo evidence for trigeminovascular activation in cluster headache. Neuropeptide changes and effects of acute attacks therapies. Brain. 1994;117 ( Pt 3):427-434. 69. Snoer A, Vollesen ALH, Beske RP, et al. Calcitonin-gene related peptide and disease activity in cluster headache. Cephalalgia. 2019;39(5):575-584.
RkJQdWJsaXNoZXIy MTk4NDMw